Cargando…

Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy

OBJECTIVE: To study the effect of reducing the duration of rifampicin therapy in the treatment of Chronic Central Serous Chorioretinopathy. METHODS: This is interventional study conducted in Layton Rahmatullah Benevolent Trust, Free Base Eye Hospital Korangi, Karachi from February 2017 - December 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Loya, Hina, Ghoghari, Hunain, Rizvi, Syed Fawad, Khan, Abdullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861499/
https://www.ncbi.nlm.nih.gov/pubmed/31777516
http://dx.doi.org/10.12669/pjms.35.6.990
_version_ 1783471371545739264
author Loya, Hina
Ghoghari, Hunain
Rizvi, Syed Fawad
Khan, Abdullah
author_facet Loya, Hina
Ghoghari, Hunain
Rizvi, Syed Fawad
Khan, Abdullah
author_sort Loya, Hina
collection PubMed
description OBJECTIVE: To study the effect of reducing the duration of rifampicin therapy in the treatment of Chronic Central Serous Chorioretinopathy. METHODS: This is interventional study conducted in Layton Rahmatullah Benevolent Trust, Free Base Eye Hospital Korangi, Karachi from February 2017 - December 2018. This randomized controlled comparative study included two groups, Groups-A comprised of 48 eyes of 40 cases with Chronic Central Serous Chorioretinopathy who were given reduced dose of oral rifampicin i.e. 600mg for one month, and Group-B consisted of 43 eyes of 40 controls with Chronic Central Serous Chorioretinopathy who were given reduced dose of oral rifampicin i.e. 300mg once daily for three months as previously stated in literature. To access the effect of therapy in both the groups, pre-treatment visual acuity on the logMAR and Optical Coherent Tomography (OCT, Heidelberg spectralis) for CMT were performed and repeated on the 1(st) and 3(rd) month post-treatment. Patients were also followed for 6 months to access any recurrence. RESULTS: On comparing the two groups, Group-A had improvement in VA and CMT after one month therapy of Rifampicin, Pre-treatment mean VA in Group-A was 0.85 ± 0.19 as compared to the pre-treatment mean VA in Group-B i.e. 0.74+/- 0.208, while the pre-treatment mean CMT was 609.0 ± 178.29 µm in Group-A, and 600.0 +/- 155.09 µm in Group-B respectively. After 1 month of therapy, the visual status, and CMT in Group-A was 0.29+/- 0.21 and 311.6 +/- 89.9, while Group-B, VA was 0.598 +/- 0.23 (p value 0.001%) and CMT was 512.30 +/- 148.37 (p-value 0.001%). Rifampicin was continued in Group-B till three months, and patients were re-accessed but there was no difference in VA and CMT statically. During the 3(rd) and 6(th) months of follow up no relapses were reported. CONCLUSION: This comparative study showed that the group receiving oral rifampicin 600mg for one month showed better outcome at one month and third month than the group receiving oral rifampicin at a dose of 300mg once daily for three months. This gives a better compliance and lower the risk of drug induced side effects.
format Online
Article
Text
id pubmed-6861499
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-68614992019-11-27 Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy Loya, Hina Ghoghari, Hunain Rizvi, Syed Fawad Khan, Abdullah Pak J Med Sci Original Article OBJECTIVE: To study the effect of reducing the duration of rifampicin therapy in the treatment of Chronic Central Serous Chorioretinopathy. METHODS: This is interventional study conducted in Layton Rahmatullah Benevolent Trust, Free Base Eye Hospital Korangi, Karachi from February 2017 - December 2018. This randomized controlled comparative study included two groups, Groups-A comprised of 48 eyes of 40 cases with Chronic Central Serous Chorioretinopathy who were given reduced dose of oral rifampicin i.e. 600mg for one month, and Group-B consisted of 43 eyes of 40 controls with Chronic Central Serous Chorioretinopathy who were given reduced dose of oral rifampicin i.e. 300mg once daily for three months as previously stated in literature. To access the effect of therapy in both the groups, pre-treatment visual acuity on the logMAR and Optical Coherent Tomography (OCT, Heidelberg spectralis) for CMT were performed and repeated on the 1(st) and 3(rd) month post-treatment. Patients were also followed for 6 months to access any recurrence. RESULTS: On comparing the two groups, Group-A had improvement in VA and CMT after one month therapy of Rifampicin, Pre-treatment mean VA in Group-A was 0.85 ± 0.19 as compared to the pre-treatment mean VA in Group-B i.e. 0.74+/- 0.208, while the pre-treatment mean CMT was 609.0 ± 178.29 µm in Group-A, and 600.0 +/- 155.09 µm in Group-B respectively. After 1 month of therapy, the visual status, and CMT in Group-A was 0.29+/- 0.21 and 311.6 +/- 89.9, while Group-B, VA was 0.598 +/- 0.23 (p value 0.001%) and CMT was 512.30 +/- 148.37 (p-value 0.001%). Rifampicin was continued in Group-B till three months, and patients were re-accessed but there was no difference in VA and CMT statically. During the 3(rd) and 6(th) months of follow up no relapses were reported. CONCLUSION: This comparative study showed that the group receiving oral rifampicin 600mg for one month showed better outcome at one month and third month than the group receiving oral rifampicin at a dose of 300mg once daily for three months. This gives a better compliance and lower the risk of drug induced side effects. Professional Medical Publications 2019 /pmc/articles/PMC6861499/ /pubmed/31777516 http://dx.doi.org/10.12669/pjms.35.6.990 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Loya, Hina
Ghoghari, Hunain
Rizvi, Syed Fawad
Khan, Abdullah
Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy
title Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy
title_full Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy
title_fullStr Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy
title_full_unstemmed Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy
title_short Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy
title_sort effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861499/
https://www.ncbi.nlm.nih.gov/pubmed/31777516
http://dx.doi.org/10.12669/pjms.35.6.990
work_keys_str_mv AT loyahina effectofalteringtheregimeoforalrifampicintherapyinthetreatmentofpersistentcentralserouschorioretinopathy
AT ghogharihunain effectofalteringtheregimeoforalrifampicintherapyinthetreatmentofpersistentcentralserouschorioretinopathy
AT rizvisyedfawad effectofalteringtheregimeoforalrifampicintherapyinthetreatmentofpersistentcentralserouschorioretinopathy
AT khanabdullah effectofalteringtheregimeoforalrifampicintherapyinthetreatmentofpersistentcentralserouschorioretinopathy